Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study

Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study

Background: Bisphosphonates are contraindicated in patients with stage 4+ chronic kidney disease. However, they are widely used to prevent fragility fractures in stage 3 chronic kidney disease, despite a lack of good-quality data on their effects. Objectives: The aims of each work package were as fo...

Full description

Bibliographic Details
Main Authors: Danielle E Robinson, M Sanni Ali, Victoria Y Strauss, Leena Elhussein, Bo Abrahamsen, Nigel K Arden, Yoav Ben-Shlomo, Fergus Caskey, Cyrus Cooper, Daniel Dedman, Antonella Delmestri, Andrew Judge, Muhammad Kassim Javaid, Daniel Prieto-Alhambra
Format: Article
Language:English
Published: NIHR Journals Library 2021-03-01
Series:Health Technology Assessment
Subjects:
bisphosphonates
chronic kidney disease
chronic kidney disease-mineral and bone disorder
pharmacoepidemiology
fracture
Online Access:https://doi.org/10.3310/hta25170

Internet

https://doi.org/10.3310/hta25170

Similar Items